Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Reunion Neuroscience Inc T.REUN

Healthcare Biotechnology
Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a... see more

Recent & Breaking News (TSX:REUN)

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

GlobeNewswire February 2, 2023

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

GlobeNewswire January 18, 2023

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

GlobeNewswire January 9, 2023

Reunion Neuroscience Inc. Provides 2023 Corporate Update

GlobeNewswire January 4, 2023

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences in December

GlobeNewswire December 6, 2022

Reunion Neuroscience Puts in Place At-The-Market Equity Facility

GlobeNewswire November 18, 2022

Reunion Neuroscience Inc. Provides Business Update and Reports Fiscal Second Quarter 2023 Financial Results

GlobeNewswire November 14, 2022

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday, November 14, 2022, at 8:30 A.M. ET

GlobeNewswire November 7, 2022

Reunion Neuroscience to Present at Upcoming November Conferences

GlobeNewswire October 31, 2022

Reunion Neuroscience Opens the Market

Canada NewsWire October 25, 2022

Reunion Neuroscience (TSX:REUN) appoints new CFO and Vice President, Medical Affairs

Shoran Devi October 24, 2022

Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs

GlobeNewswire October 24, 2022

Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference

GlobeNewswire October 12, 2022

Reunion Neuroscience Inc. Announces Executive Changes

GlobeNewswire October 7, 2022

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

GlobeNewswire October 3, 2022

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting

GlobeNewswire September 29, 2022

Reunion (TSX:REUN) appoints Greg Mayes as President and CEO

Azuka Onwuka September 28, 2022

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer

GlobeNewswire September 28, 2022

Reunion Neuroscience Inc. to Participate in Upcoming Investor Conferences

GlobeNewswire September 8, 2022

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

GlobeNewswire August 31, 2022